This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Going Deeper on Atopic Dermatitis: Pathophysiology to the Management of Moderate-to-Severe Disease

Going Deeper on Atopic Dermatitis: Pathophysiology to the Management of Moderate-to-Severe Disease

Format

Webcast

Time to Complete

1 hour

Released

September 6, 2017

Expires

September 6, 2018
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

This activity is jointly provided by Global Education Group and Integritas Communications.

Commercial Supporter

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Program Description/Statement of Need

Atopic dermatitis is a chronic inflammatory condition with manifestations in the skin and in other organ systems throughout the body.1 Increasing in prevalence over the last 2 decades, the disease places tremendous burdens on patients, family members, and caregivers.1,2 The evolving understanding of disease pathophysiology and widespread effects on patient health and quality of life highlight the need for prompt diagnosis and proactive management.3,4 Moreover, research into the mechanisms underlying atopic dermatitis pathogenesis and progression has led to new approaches to disease characterization and treatment.5,6 This Interactive ExchangeTM  program will open with a brief 3D-animated video highlighting mechanistic insights into atopic dermatitis development. Expert faculty will then discuss best practices in comprehensive patient evaluations, and the clinical profiles, efficacy, and safety of treatment options for moderate-to-severe disease, including biologic therapy. With the overall goal of improving outcomes for patients with moderate-to-severe atopic dermatitis, the program will integrate clinical data and professional experience into actionable recommendations that can be used to individualize care and improve patient-clinician communication.
________________________________________________

References
1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
2. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
3. Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.
4. Sidbury R, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2): 327-349.
5. Ungar B, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603-613.
6. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.

Intended Audience

The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with moderate-to-severe atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Discuss pathophysiologic mechanisms and risk factors that contribute to atopic dermatitis development and persistence, including potential treatment targets
  • Evaluate patients with atopic dermatitis over time for persistent symptoms, comorbidities, and treatment responses
  • Describe the clinical profiles of current and emerging biologic therapies for moderate-to-severe atopic dermatitis
  • Tailor long-term therapy for moderate-to-severe atopic dermatitis to prevent exacerbations, maximize, health-related quality of life, manage comorbidities, and minimize adverse events
  • Educate patients and caregivers to improve their understanding of atopic dermatitis, provide Action Plans to reduce exacerbations, and promote shared decision-making

Conflict Of Interest Disclosure Policy

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty

Jeffrey M. Weinberg, MD
Associate Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York
Director, Division of Dermatology
Jamaica Hospital Medical Center
Richmond Hill, NY

Dr. Weinberg discloses the following:
Grant/Research Support: Regeneron Pharmaceuticals, Inc.

Lawrence F. Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
University of California, San Diego, School of Medicine
Chief, Pediatric and Adolescent Dermatology
Rady Children’s Hospital
San Diego, CA

Dr. Eichenfield discloses the following:
Consultant/Independent Contractor: Anacor Pharmaceuticals, Inc.; Eli Lilly and Company; Genentech, Inc.; Medimetriks Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC.; Top MD, Inc.; Valeant Pharmaceuticals International, Inc.
Grant/Research Support: Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC.

Melinda Gooderham, MD, FRCPC
Assistant Professor
Queen’s University
Kingston, Ontario, Canada
Medical Director
SKiN Centre for Dermatology
Peterborough, Ontario, Canada

Dr. Gooderham discloses the following:
Consultant/Independent Contractor: Akros Pharma Inc.; Boehringer Ingelheim International GmbH; Eli Lilly and Company; Janssen Inc.; Kyowa Hakko Kirin Co., Ltd.
Grant/Research Support: AbbVie Inc.; Akros Pharma Inc.; Amgen Inc; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Celgene Corporation; Dermira, Inc.; Galderma SA; Janssen Inc.; Kyowa Hakko Kirin Co., Ltd.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Roche Laboratories, Inc.; UCB, Inc.
Honoraria: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma SA; Janssen Inc.; LEO Pharma A/S; MedImmune, LLC; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Canada; Valeant Pharmaceuticals International, Inc.
Speakers Bureau: AbbVie Inc.; Actelion Pharmaceuticals US, Inc.; Amgen Inc.; Eli Lilly and Company; Galderma SA; Janssen Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Sanofi Canada; Valeant Pharmaceuticals International, Inc.

Planners' and Managers' Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME/CE activity:

Ashley Marostica, RN, MSN, has nothing to disclose.
Andrea Funk has nothing to disclose.
Rose O’Connor, PhD, has nothing to disclose.
Jim Kappler, PhD, has nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Global Education Group designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee and Refund / Cancellation Policy

There is no fee for this educational activity.

Instructions

In order to receive credit, participants must complete the preactivity questionnaire, post-test, and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

If you have any other questions relating to your certificate or other issues with the activity, please contact
myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue